Yaocheng Health Technologies Completes Tens of Millions of USD Series A+ Financing to Empower Digital Transformation in Life Sciences Clinical Research

On October 12, 2022 (Beijing Time), Shanghai Yaosheng Health Technology Co., Ltd. (hereinafter referred to as “Yaosheng Health Tech” or “Yaosheng”), a pioneer in empowering next-generation life science clinical research with digital intelligence, officially completed its tens-of-millions-of-US-dollars Series A+ financing round. The lead investor was Hankang Capital (an existing investor from Yaosheng’s seed and Series A rounds), with B Capital participating as a follow-on investor. China Renaissance served as the exclusive financial advisor for this financing round.

Yaocheng Health Technology was officially established in early August 2020, with its headquarters in Shanghai, China. The company is dedicated to leveraging globally leading computer technologies to achieve comprehensive informatization and intelligence across all scenarios and the entire value chain of life science clinical research, thereby helping the life sciences industry reduce costs and improve efficiency during the innovative R&D phase. The Yaocheng team primarily comprises professionals from global industry leaders such as Google, Verily, Splunk, Medidata, Veeva, and WuXi AppTec.

In May 2021, AspireNT launched AuroraPrime 1.0, a new-generation cloud platform for clinical research designed for the future, and completed an RMB 100 million Series A financing round in July of the same year. In May 2022, the company released AuroraPrime 2.0 online, achieving full-process integration and digitalization of clinical trials starting from protocol development, and officially announced its product strategy to fully embrace Decentralized Clinical Trials (DCT). In August 2022, AspireNT officially moved into the Shanghai SK Tower, a landmark building in the Houtan area of Pudong, Shanghai.

Ms. Chen Xiao, CEO of Yaosheng Health Technologystated: “MegaTrans is a technology-driven startup. Our product and R&D teams are primarily composed of talent from globally leading high-tech enterprises. Since our founding in 2020, we have been dedicated to exploring the vast possibilities of empowering life science clinical research through innovations in computer science. From achieving true integration at the underlying system architecture to developing innovative, intelligent applications across multiple specialized, deep-dive scenarios, the MegaTrans team has solidly delivered on our promises to clients and investors. Leveraging our profound understanding of diverse scenarios within the clinical research domain, the MegaTrans AuroraPrime Clinical Research Platform starts with protocol writing and is powered by its core Clinical Logic Engine, thereby establishing a comprehensive framework for the flow, accumulation, and application of data across the entire clinical trial lifecycle. With world-leading technical capabilities and product design philosophies, we are bringing users a new era of informatization and intelligence in clinical research.”

Mr. Zhang Zhi, Chief Business Officer of Yaocheng Health Tech“Yaocheng places paramount importance on customer success. We possess a profound understanding of industry needs and continuously explore future trends to deliver truly ideal system user experiences and application value. Our product R&D team combines forward-thinking design philosophy with creative implementation capabilities, earning widespread recognition from industry experts for Yaocheng’s products upon their launch. From traditional EDC and RTSM systems to Yaocheng’s innovative intelligent protocol writing system, remote intelligent clinical research systems, and a broader portfolio of future-oriented, data-driven intelligent clinical systems, Yaocheng has established deep collaborations with numerous leading enterprises in the life sciences innovation sector, both domestically and internationally.”

Mr. Yuan Quanhong, Managing Partner at Hankang Capital“HeKang Capital has always been dedicated to supporting outstanding innovative enterprises in the life sciences industry, accompanying them on their journey to success. In the process of pharmaceutical innovation, the importance of clinical research is unquestionable. While ensuring compliance, companies should fully leverage information technology to enhance the efficiency of data flow and application in clinical trials, thereby accelerating the market launch of innovative drugs. Medicxi is precisely such an innovative enterprise with leading technologies, spearheading the trend toward informatization in clinical trials.”

Ms. Cai Wei, Managing Partner and Head of China at B Capital“Clinical trial software, as a product category driven by regulatory imperatives, boasts substantial market potential. Amid the current industry trends toward decentralized clinical trials and integrated platforms, innovative companies with strong capabilities are well-positioned to accelerate their growth. The Boston Investment team has long focused on the healthcare and enterprise services sectors, and we highly recognize YC’s top-tier product development and innovation capabilities in this cross-disciplinary field. We are pleased to see that, within two years since its establishment, YC has continuously expanded its product portfolio, achieved rapid order growth, and gained recognition and adoption from multiple leading pharmaceutical companies. Boston Investment looks forward to deepening its collaboration with YC and providing support in areas such as international expansion.”

Mr. Xie Yijing, Managing Director and Head of the Healthcare and Life Sciences Group at China Renaissancestated: “We are honored to have assisted Mazu HealthTech in closing this round of financing. The cross-disciplinary team at Mazu HealthTech possesses a deep understanding of clinical research needs in the life sciences sector. By adopting a forward-looking strategic layout that is rooted locally while maintaining a global perspective, the company has rapidly established an integrated and intelligent digital platform for life sciences clinical operations, leveraging its strong technological capabilities and execution efficiency. This has accelerated the digital transformation of clinical research in the life sciences industry. We believe that, with the continued support of both existing and new shareholders, Mazu HealthTech will accelerate its growth and continue to empower the life sciences sector as it enters a new era of digitalization and intelligence.”

Yaocheng Health Technologies focuses on the clinical R&D sector of life sciences and is committed to pioneering a globally leading next-generation SaaS platform for clinical research. By leveraging technologies such as cloud computing, big data, and AI, the company empowers trial design, data management, and operations in life sciences R&D. This ensures clinical data consistency, enhances design and execution efficiency, optimizes cost control, and accelerates the commercialization of innovative drugs and novel medical devices, ultimately advancing human health.

Hankang Capital is a venture capital fund dedicated to the pharmaceutical and healthcare industry. Guided by its mission to “empower pharmaceutical innovation and safeguard human health,” the fund collaborates with top-tier scientists and entrepreneurs to jointly develop breakthrough novel drugs for the treatment of major diseases. Rooted in China with a global perspective, Hankang Capital has invested in numerous companies that have grown into industry leaders, including InnoCare Pharma (09969.HK), Akeso Biopharma (09926.HK), Keymed Biosciences (02162.HK), Chipscreen Biosciences (688321.SH), and Abace Therapeutics (02256.HK).

B Capital is a partner-oriented investment fund with unique global resources and a top-tier consulting background, dedicated to providing deep empowerment to enterprises. The fund currently maintains offices in eight cities across Asia and North America, with approximately $6.5 billion in assets under management. B Capital focuses on enterprise services, healthcare, the global expansion of Chinese companies, and climate sustainability, investing across all stages of the corporate lifecycle. Leveraging its strategic, round-the-clock partnership with Boston Consulting Group (BCG), B Capital provides entrepreneurs with access to business resources and comprehensive support.

China Renaissance Holdings was established in 2005. As a leading integrated financial services institution, its business spans investment management, private financing, mergers and acquisitions, securities issuance and underwriting, securities research and trading, wealth management, and other services. Over the past 17 years, serving as a trusted capital markets partner to thousands of entrepreneurs in the innovation economy, we have remained committed to identifying the most exceptional companies, collaborating with them to create value, and playing a vital ecological role in the booming innovation economy.